Skip to main content
Fig. 1 | Journal of Nanobiotechnology

Fig. 1

From: How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions

Fig. 1

Schematic representation of IgG antibody structure (A) consisting of a shorter light chain (pink) and a long heavy chain (orange), the constant region (Fc, marked in blue), and its antigen-binding fragment (Fab, marked in green). VL: light chain variable region; VH: heavy chain variable region; CL: a constant region of the light chain; (CH1, CH2, CH3): regions of the heavy chain labeled 1, 2, 3, respectively. Schematic structure of infliximab (B) and adalimumab (C) [own drawing]

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us